Abstract
Simultaneous appearance of hypertension, diabetes, dyslipidemia and obesity is recently recognised as cardiometabolic risk. Dyslipidemia and hypertension share some common patophysiologic mechanisms, leasing to aterotrombosis, and are frequently similar to other cardiovascular risk factors.
Common pathway include increased activity of RAS (renin angiotensin system), which applies both to hypertension and activates as dyslipidemia does endothelial dysfunction, inflammation and thrombosis. It seems that statins slightly, but significantly decrease blood preasure in patients with increased (not normal) ambulatory monitored blood preasure.
The choice of suitable antihypertensive agents is essential in the treatment of hypertension and dyslipidemia to reduce the cardiovascular risk (the dose and combination of drugs, namely statins and RAS inhibitors).